Diogo Haddad Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diogo Haddad Santos has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Anderson Matheus Pereira da Silva
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, Brazil
8 shared publications - Rafael Paternò Castello Dias-Carneiro
Irmandade da Santa Casa de São Paulo, Serviço de Neurologia, São Paulo SP, Brazil
5 shared publications - Carolina Braga Moura
Irmandade Santa Casa da Misericórdia de São Paulo, São Paulo SP, Brazil
4 shared publications - Guilherme Sciascia Do Olival
Santa Casa de São Paulo, Faculdade de Ciências Médicas, São Paulo SP, Brazil
4 shared publications Bruno Cassis Rodrigues
Santa Casa de São Paulo
3 shared publicationsEliana Tomomi Cunha
Santa Casa de São Paulo
3 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
Comment on “Alzheimer Disease Patients Who Survived COVID-19 Have Rapid Disease Progression and a Higher Risk of Death at 5-Year Follow-Up”
Was not provided for this article.
- 20 October 2026
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
Comment on “Alzheimer Disease Patients Who Survived COVID-19 Have Rapid Disease Progression and a Higher Risk of Death at 5-Year Follow-Up”
Was not provided for this article.
- Open Access
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
Sex-Based Differences in Short- and Long-Term All-Cause Mortality in Creutzfeldt-Jakob Disease: A Real-World, Age-Matched Federated Electronic Health Record Cohort Study
Background Creutzfeldt-Jakob disease (CJD) has a universally poor prognosis, but whether recorded sex is associated with mortality remains poorly characterized.,Objective To evaluate whether recorded sex is associated with all-cause mortality within 90 to 730 days after the first recorded CJD diagnosis in a global federated EHR network, adjusting for clinical and pharmacological severity markers.,Methods We conducted a retrospective cohort study using the TriNetX network. Patients with CJD (ICD-10-CM A81.0) were assigned to female or male cohorts, with male sex as reference. A primary Cox model estimated the 2-year sex-mortality association; two secondary Cox models added medications and complications. Secondary age-matched analyses (1:1 on age) compared mortality at 90, 180, 365, and 730 days.,Results The unmatched cohort included 1,395 female and 1,327 male patients (mean age, 73.9 vs 72.3 years). In the primary model, female sex was associated with lower 2-year mortality hazard, with a confidence interval that included the null (HR 0.885, 95% CI 0.775–1.010, P = 0.069); two secondary models adjusted for medications or complications yielded intervals excluding the null (HR, 0.867 and 0.866; P = 0.035 and 0.030). In secondary age-matched analyses, only the 90-day risk difference (931 matched pairs) excluded the null (-4.6 points, 95% CI -8.8 to -0.5, P = 0.029); no other window or hazard-based measure did.,Conclusions Recorded female sex was associated with lower all-cause mortality after CJD diagnosis, reaching significance only in adjusted Cox models and the 90-day matched comparison. These hypothesis-generating findings warrant confirmation in molecularly characterized prospective cohorts.
- 5 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSex-Based Differences in Short- and Long-Term All-Cause Mortality in Creutzfeldt-Jakob Disease: A Real-World, Age-Matched Federated Electronic Health Record Cohort Study
Background Creutzfeldt-Jakob disease (CJD) has a universally poor prognosis, but whether recorded sex is associated with mortality remains poorly characterized.,Objective To evaluate whether recorded sex is associated with all-cause mortality within 90 to 730 days after the first recorded CJD diagnosis in a global federated EHR network, adjusting for clinical and pharmacological severity markers.,Methods We conducted a retrospective cohort study using the TriNetX network. Patients with CJD (ICD-10-CM A81.0) were assigned to female or male cohorts, with male sex as reference. A primary Cox model estimated the 2-year sex-mortality association; two secondary Cox models added medications and complications. Secondary age-matched analyses (1:1 on age) compared mortality at 90, 180, 365, and 730 days.,Results The unmatched cohort included 1,395 female and 1,327 male patients (mean age, 73.9 vs 72.3 years). In the primary model, female sex was associated with lower 2-year mortality hazard, with a confidence interval that included the null (HR 0.885, 95% CI 0.775–1.010, P = 0.069); two secondary models adjusted for medications or complications yielded intervals excluding the null (HR, 0.867 and 0.866; P = 0.035 and 0.030). In secondary age-matched analyses, only the 90-day risk difference (931 matched pairs) excluded the null (-4.6 points, 95% CI -8.8 to -0.5, P = 0.029); no other window or hazard-based measure did.,Conclusions Recorded female sex was associated with lower all-cause mortality after CJD diagnosis, reaching significance only in adjusted Cox models and the 90-day matched comparison. These hypothesis-generating findings warrant confirmation in molecularly characterized prospective cohorts.
- Open Access
- 17 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 794
Amyloid-beta-targeting monoclonal antibodies in early Alzheimer’s disease: a cochrane review summary and appraisal for the neurological community
Background: Seven amyloid-beta-targeting monoclonal antibodies have been trialled in early Alzheimer’s disease. They differ in epitope and in how much plaque they clear; only two have traditional approval. A 2026 Cochrane Review pooled all seven as one class. We ask what that average tells us about any one drug. Methods: We summarise the review in mild cognitive impairment or mild dementia due to Alzheimer’s disease and report its estimates and certainty ratings unchanged. Our appraisal sits in a separate section and draws on the pivotal trials and regulatory assessments. Results: Seventeen trials (20,342 participants) were included. At 18 months the pooled standardised mean difference was −0.11 (95 % confidence interval −0.16 to −0.06) for cognition and −0.12 (−0.24 to 0.00) for dementia severity; three functional scales favoured treatment (0.09 to 0.23). Amyloid-related imaging abnormalities with oedema affected 119 versus 12 per 1,000 (risk ratio 10.02, 7.49 to 13.41). Four of the seven antibodies cleared no plaque or cleared it incompletely, so the pooled result cannot test whether clearance produces benefit. In the two approved agents dementia severity differed by 0.45 and 0.67 points, larger than the class average but below thresholds of clinical importance. Conclusions: The class average is not an estimate for any single agent. These antibodies clear amyloid and produce small differences on trial scales at 18 months, against a tenfold rise in amyloid-related oedema. Counselling should rest on agent-specific figures and a biomarker-confirmed diagnosis, and should weigh APOE ε4 genotype and antithrombotic use before the first infusion.
- 17 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 794
Open AccessAmyloid-beta-targeting monoclonal antibodies in early Alzheimer’s disease: a cochrane review summary and appraisal for the neurological community
Background: Seven amyloid-beta-targeting monoclonal antibodies have been trialled in early Alzheimer’s disease. They differ in epitope and in how much plaque they clear; only two have traditional approval. A 2026 Cochrane Review pooled all seven as one class. We ask what that average tells us about any one drug. Methods: We summarise the review in mild cognitive impairment or mild dementia due to Alzheimer’s disease and report its estimates and certainty ratings unchanged. Our appraisal sits in a separate section and draws on the pivotal trials and regulatory assessments. Results: Seventeen trials (20,342 participants) were included. At 18 months the pooled standardised mean difference was −0.11 (95 % confidence interval −0.16 to −0.06) for cognition and −0.12 (−0.24 to 0.00) for dementia severity; three functional scales favoured treatment (0.09 to 0.23). Amyloid-related imaging abnormalities with oedema affected 119 versus 12 per 1,000 (risk ratio 10.02, 7.49 to 13.41). Four of the seven antibodies cleared no plaque or cleared it incompletely, so the pooled result cannot test whether clearance produces benefit. In the two approved agents dementia severity differed by 0.45 and 0.67 points, larger than the class average but below thresholds of clinical importance. Conclusions: The class average is not an estimate for any single agent. These antibodies clear amyloid and produce small differences on trial scales at 18 months, against a tenfold rise in amyloid-related oedema. Counselling should rest on agent-specific figures and a biomarker-confirmed diagnosis, and should weigh APOE ε4 genotype and antithrombotic use before the first infusion.
- 10 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (1) , 84-86
GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program
The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brain penetration. We argue that attrited extension cohorts bear limited inferential weight and that the biomarker substudy, read in full, complicates a clean disease-modification reading. EVOKE does not refute the cardiometabolic hypothesis but reframes the open questions: which pathways, which patients, and which disease stages are most likely to benefit.
- 10 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (1) , 84-86
GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program
The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brain penetration. We argue that attrited extension cohorts bear limited inferential weight and that the biomarker substudy, read in full, complicates a clean disease-modification reading. EVOKE does not refute the cardiometabolic hypothesis but reframes the open questions: which pathways, which patients, and which disease stages are most likely to benefit.
- Open Access
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 212-219
Late-onset unprovoked seizures and subsequent risk of dementia in older adults: A target trial emulation
- 29 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 212-219
Open AccessLate-onset unprovoked seizures and subsequent risk of dementia in older adults: A target trial emulation
- Open Access
GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Purpose: People with type 2 diabetes mellitus (DM2) have an increased risk of Alzheimer’s Disease (AD). GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) have emerged as potential interventions to prevent AD and dementia and may provide insights into disease mechanisms. Methods: PubMed, Embase, and Cochrane were searched for randomized controlled trials (RCTs), cohort, and case-control studies between January 1, 2006, and April 15, 2025, comparing GLP-1RAs and/or SGLT2i in adults with DM2 without cognitive impairment at baseline. A total of 12 studies met the inclusion criteria (1 RCT and 11 cohort studies). The primary outcome was incident AD and dementia, assessed primarily through adjusted hazard ratio (HR). Secondary outcomes were HbA1C levels and their relation to cognitive protection. A regression analysis was performed to assess the variables that could explain the result obtained. Results: GLP-1RAs and SGLT2i consistently demonstrated a reduced risk of AD (HR = 0.72; 95% CI, 0.59–0.87) and dementia (HR = 0.84; 95% CI, 0.76–0.92) compared to other glucose-lowering therapies, with moderate/high heterogeneity and moderate certainty. Also, SGLT2i showed a modest benefit over GLP-1RAs in protecting against AD (HR = 1.07; 95% CI, 1.00–1.14; p = 0.0496), and baseline HbA1c was associated with AD risk estimates among SGLT2i users but not among GLP-1RA users. Conclusion: These findings reinforce the potential of GLP-1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation.
Open AccessGLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Purpose: People with type 2 diabetes mellitus (DM2) have an increased risk of Alzheimer’s Disease (AD). GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) have emerged as potential interventions to prevent AD and dementia and may provide insights into disease mechanisms. Methods: PubMed, Embase, and Cochrane were searched for randomized controlled trials (RCTs), cohort, and case-control studies between January 1, 2006, and April 15, 2025, comparing GLP-1RAs and/or SGLT2i in adults with DM2 without cognitive impairment at baseline. A total of 12 studies met the inclusion criteria (1 RCT and 11 cohort studies). The primary outcome was incident AD and dementia, assessed primarily through adjusted hazard ratio (HR). Secondary outcomes were HbA1C levels and their relation to cognitive protection. A regression analysis was performed to assess the variables that could explain the result obtained. Results: GLP-1RAs and SGLT2i consistently demonstrated a reduced risk of AD (HR = 0.72; 95% CI, 0.59–0.87) and dementia (HR = 0.84; 95% CI, 0.76–0.92) compared to other glucose-lowering therapies, with moderate/high heterogeneity and moderate certainty. Also, SGLT2i showed a modest benefit over GLP-1RAs in protecting against AD (HR = 1.07; 95% CI, 1.00–1.14; p = 0.0496), and baseline HbA1c was associated with AD risk estimates among SGLT2i users but not among GLP-1RA users. Conclusion: These findings reinforce the potential of GLP-1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation.
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1143-1158
Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review
Background: Sex-specific vulnerability to Alzheimer's disease (AD) has been increasingly recognized, with menopause representing a decisive neuroendocrine transition. Estrogen and progesterone modulate synaptic plasticity, glucose metabolism, and amyloid-tau homeostasis, yet the impact of their decline and replacement remains controversial. AD biomarkers provide objective means to assess menopausal hormone therapy (MHT) mechanistic effects beyond cognitive endpoints. Objective: To determine how MHT influences validated AD biomarkers in peri- and postmenopausal women. Methods: A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251149404). PubMed, Embase, Web of Science, and Cochrane Library were searched through September 2025 for interventional and observational studies evaluating MHT and AD biomarkers after non-surgical menopause. Eligible biomarkers included cerebrospinal fluid (CSF) and plasma markers, and amyloid-, tau- or FDG-PET imaging. Study quality was assessed using RoB-2 and ROBINS-I tools, and evidence certainty with GRADE. Results: Fourteen studies met inclusion criteria. Early or continuous transdermal 17β-estradiol was linked with lower CSF and plasma p-tau181 and preserved glucose metabolism in AD-vulnerable cortical regions. Neuroimaging studies showed decreased amyloid deposition and sustained metabolic benefits years after discontinuation. Conversely, oral conjugated equine estrogens and estrogen-progestin regimens led to neutral or unfavorable biomarker trends, particularly when initiated more than five years after menopause. Conclusions: MHT's effects on AD biomarkers depend on timing, formulation and hormonal composition. Early transdermal estradiol appears to reinforce neuroprotective biomarker profiles, whereas delayed or combined therapies may nullify these benefits. Genotype-stratified trials with harmonized biomarker reports are needed to define optimal neuroprotective windows for women.
- 16 June 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (3) , 1143-1158
Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review
Background: Sex-specific vulnerability to Alzheimer's disease (AD) has been increasingly recognized, with menopause representing a decisive neuroendocrine transition. Estrogen and progesterone modulate synaptic plasticity, glucose metabolism, and amyloid-tau homeostasis, yet the impact of their decline and replacement remains controversial. AD biomarkers provide objective means to assess menopausal hormone therapy (MHT) mechanistic effects beyond cognitive endpoints. Objective: To determine how MHT influences validated AD biomarkers in peri- and postmenopausal women. Methods: A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251149404). PubMed, Embase, Web of Science, and Cochrane Library were searched through September 2025 for interventional and observational studies evaluating MHT and AD biomarkers after non-surgical menopause. Eligible biomarkers included cerebrospinal fluid (CSF) and plasma markers, and amyloid-, tau- or FDG-PET imaging. Study quality was assessed using RoB-2 and ROBINS-I tools, and evidence certainty with GRADE. Results: Fourteen studies met inclusion criteria. Early or continuous transdermal 17β-estradiol was linked with lower CSF and plasma p-tau181 and preserved glucose metabolism in AD-vulnerable cortical regions. Neuroimaging studies showed decreased amyloid deposition and sustained metabolic benefits years after discontinuation. Conversely, oral conjugated equine estrogens and estrogen-progestin regimens led to neutral or unfavorable biomarker trends, particularly when initiated more than five years after menopause. Conclusions: MHT's effects on AD biomarkers depend on timing, formulation and hormonal composition. Early transdermal estradiol appears to reinforce neuroprotective biomarker profiles, whereas delayed or combined therapies may nullify these benefits. Genotype-stratified trials with harmonized biomarker reports are needed to define optimal neuroprotective windows for women.
- Open Access
- 11 June 2026
- Published by Elsevier in AJO International
- Vol. 3 (3)
GLP-1 receptor agonists and ischemic optic neuropathy in patients with type 2 diabetes and obesity: A TriNetX cohort study
- 11 June 2026
- Published by Elsevier in AJO International
- Vol. 3 (3)
Open AccessGLP-1 receptor agonists and ischemic optic neuropathy in patients with type 2 diabetes and obesity: A TriNetX cohort study
- 7 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (1) , 116-117
Methodological considerations on the network meta-analysis of brexpiprazole dosing for agitation in Alzheimer's disease
- 7 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 112 (1) , 116-117
Methodological considerations on the network meta-analysis of brexpiprazole dosing for agitation in Alzheimer's disease